Baird Maintains Neutral on Regeneron Pharmaceuticals, Lowers Price Target to $760
Portfolio Pulse from richadhand@benzinga.com
Baird analyst Brian Skorney has maintained a Neutral rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and lowered the price target from $800 to $760.
June 28, 2023 | 2:08 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Regeneron Pharmaceuticals' price target has been lowered from $800 to $760 by Baird, while maintaining a Neutral rating.
The news directly pertains to Regeneron Pharmaceuticals as Baird has lowered its price target for the company. This could potentially influence investor sentiment and impact the stock's price, although the Neutral rating suggests that the overall outlook for the company remains unchanged.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100